Naveris blood test spots recurrence of HPV cancers

By staff writers

February 6, 2020 -- Molecular diagnostics firm Naveris is highlighting research published online February 5 in the Journal of Clinical Oncology that demonstrates the efficacy of the company's NavDx blood test for detecting recurrent head and neck cancers associated with HPV.

The test is designed to identify tumor-modified viral HPV DNA. The prospective study, conducted by lead author Dr. Bhisham Chera of the University of North Carolina School of Medicine and colleagues, included 115 patients treated for HPV-related head and neck cancers who were tracked for recurrence for up to 3.5 years with imaging and fiber-optic nasopharyngeal endoscopy. The patients had the blood test before and during treatment and at post-treatment follow-up visits.

The blood test had a sensitivity of 100%, with all patients who eventually developed a recurrence demonstrating positive results. No patients with a negative blood test developed a recurrence, for a negative predictive value of 100%. The researchers also found the following:

  • Of the patients with two consecutive positive blood tests, all but one developed a biopsy-proven recurrence (positive predictive value of 94%).
  • A positive blood test preceded the detection of recurrence by imaging for 91% of patients, with a median lead time of 3.9 months.

The study is timely, as the incidence of HPV-related head and neck cancer has increased dramatically in recent years; it is now the most prevalent HPV-related cancer in the U.S., surpassing cervical cancer, Naveris noted.

New HPV saliva test may speed detection of mouth, throat cancers
Scientists have fused acoustics and microfluidics in a novel saliva test designed to show within minutes whether a person has a high-risk strain of HPV...
Becton Dickinson files for Onclarity FDA approval in 11 more HPV types
Becton Dickinson has submitted a premarket approval filing with the U.S. Food and Drug Administration (FDA) for its Onclarity test for an expanded number...
NeuMoDx adds HPV test with pathology spin-off Self-screen
NeuMoDx is working with the Netherlands-based biotech spin-off Self-screen on a CE-IVD Marked test for high-risk HPV that is compatible with its NeuMoDx...
ASCP tackles hepatitis C, stool pathogens, and more in new test guidelines
The American Society for Clinical Pathology (ASCP) has released five new recommendations for appropriate lab test ordering, including advice against repeat...
Test shows promise for improving HPV triage
A new test shows promise for second-line use in patients with a positive HPV result to reduce the number of unnecessary colposcopies and as a two-in-one...

Copyright © 2020

Last Updated np 2/5/2020 3:55:47 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current